We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel Anti-PTEN Rabbit Monoclonal Antibody Optimized for Immunohistochemistry Testing

By LabMedica International staff writers
Posted on 16 Sep 2013
Cancer researchers now have available a rabbit monoclonal antibody for the protein produced by the PTEN tumor suppressor gene that has been optimized for immunohistochemistry (IHC) testing.

PTEN is one of the most commonly lost tumor suppressors in human cancer. More...
During tumor development, mutations and deletions of PTEN occur that inactivate its enzymatic activity leading to increased cell proliferation and reduced cell death. Frequent genetic inactivation of PTEN occurs in glioblastoma, endometrial cancer, prostate cancer, and reduced expression is found in many other tumor types such as lung and breast cancer. When the PTEN enzyme is functioning properly, it acts as part of a chemical pathway that signals cells to stop dividing and causes cells to undergo programmed cell death (apoptosis) when necessary. These functions prevent uncontrolled cell growth that can lead to the formation of tumors. There is also evidence that the protein made by the PTEN gene may play a role in both cell movement and adhesion of cells to surrounding tissues.

A new tool for the study the PTEN enzyme was developed by Spring Bioscience (Pleasanton, CA, USA). Spring has recently added the SP218 anti-PTEN rabbit monoclonal antibody to its portfolio of antibodies for cancer research.

The SP218 anti-PTEN monoclonal antibody for IHC on FFPE (formalin-fixed, paraffin-embedded) tissue is available in 0.1, 0.5, and 1.0 mL concentrate configurations, as well as in a 7.0-mL ready-to-use format. Recommended staining protocols are available for manual, semi-automated, and fully automated platforms. SP218 is for research use only and not for use in diagnostic procedures.

"SP218's robust and consistent performance with IHC analysis is particularly important given PTEN's potential as a companion diagnostic biomarker," said Michael Rivers, general manager of Spring Bioscience. "With SP218, we are seeking to set a new gold standard across the industry by offering an extremely sensitive, highly specific antibody optimized for IHC testing that will allow researchers and pathologists to interpret PTEN status with utmost confidence. For our customers, this means we are continuing to offer unparalleled value through superior tests that lead the market in innovation, reliability, and quality."

Related Links:
Spring Bioscience



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Automated Urinalysis Solution
UN-9000
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.